A series of experiments will be carried out to further validate these results in the future, clarifying that the high expression of SLC2A1 can have the role of diagnostic CRC and that interference with SLC2A1 expression can achieve the purpose of treating tumors. This evidence concerns the gene SLC2A1 and colorectal carcinoma.